

Financial solutions


Sustainable and profitable business well worth the price

Dr. Klaus Miller, Member of the Executive Board

19th International Investors' Day London, 20 October 2016



Financial solutions: a solid contributor to our bottom line EBIT contribution 2011 - 2015




Financial solutions: reinsurance transactions ...

... including transfer of biometric risks and financing components

- Financial and traditional reinsurance
 - Achieving risk transfer and financial objectives
- Traditional reinsurance
 - Transferring insurance risk to reduce the risk and volatility in the ceding company's results


Financial reinsurance

 Structured reinsurance agreement going beyond risk management and aiming to achieve one or more specific financial objectives for the ceding company



Financial solutions: an alternative means to access capital ...

... to pursue new business, increase capital reserves, etc.



Risk is the currency in which we get paid for our service




Our extensive track record

We have successfully facilitated structured transactions right around the world







- Cash financing (acquisition costs & BATs)
- Start in Germany, UK, US followed by a worldwide roll-out
- XXX, AXXX, Solvency I relief, Solvency II, C-Ross, AG48, etc.

One important distinction: cash vs. non-cash Depending on the client's objectives and required liquidity



Cash financing

- Transaction starts with one or more cash payments from reinsurer to ceding company
- Initial amount is recuperated in the following years (incl. reinsurer's expected margin) or not if profits are not high enough due to higher claims or lapses than anticipated



Non-cash financing

- Transaction just starts with an initial claim against the reinsurer
- Claim reduces over time if and when profits emerge: outstanding amount (if any) at the end of the agreed treaty term will be settled in cash



16.4% of total gross L&H premium Financial solutions 2015




New business 2015: EUR 149 m.
Incl. failure

Same business but different markets over the years



Development of cash financing business life and health

in m. EUR



Decrease in outstanding financing (OF) of EUR 21 m. Analysis of change for the financial year 2015

in m. EUR

Underwriting year	OF 31 Dec 2014 (rest.)	Calculated interest 2015 ¹⁾	Actual repayment 2015 ²⁾	OF 31 Dec 2015	Actual expected RoR	Alternative RoR incl. failure
≤ 2006	-147	-17	48	-116	6.63%	5.49%
2007	-8	0	1	-6	5.35%	4.61%
2008	-178	-6	19	-166	7.95%	7.73%
2009	-43	-2	23	-22	9.41%	6.54%
2010	-51	-10	28	-33	8.77%	4.43%
2011	-118	-13	55	-77	10.09%	4.28%
2012	-124	-6	30	-100	7.31%	3.92%
2013	-110	-4	7	-107	8.65%	3.30%
2014	-182	-13	32	-163	7.56%	5.24%
2015	0	0	0	-149	4.94%	4.07%
Total	-961	-72	242	-940	7.29%	5.32%


- 961 - 72 + 242 - 149 = - 940

1) Incl. change of actually expected IRR in comparison to previous year

2) Partly preliminary figures

Alternative capital sources

Financial solution repayments are subject to business performance



Individual life insurance financing landscape

A general timeline of the past 15 years in the US

2005 - 2007

Captives fund XXX reserves within the capital markets via securitisations

2000 - 2005 Life financing via coinsurance

2008

Financial crisis: funded structures become very difficult to execute

Recent evolution capital financing Regulators open to alternative financing solutions

> Banks offer conditional LOC solutions but need to hedge risks


2011 - 2014

Increased use of captive structures and varying forms involving unfunded structures

Going forward

AG48 will provide extra guidance: use of captives and alternative forms of capital financing

Development of in-force US financial solution business Spike in 2015 due to one-off effect



hannover **re**®

in m. USD

Run-off profits of current in-force block

Hannover Re is 4 x "best in class by transaction type"

Reinsurer capability differentiation, US only 2015


Company	XXX	AXXX	Surplus relief	RBC	EV monetisation	Cash financing	Cont. capital
Hannover Re	48%	43%	18%	15%	3%	8%	3%
Peer 1	40%	23%	13%	13%	5%	5%	\mathbf{X}
Peer 2	15%	13%	3%	3%	\mathbf{X}	3%	\mathbf{x}
Peer 3	18%	20%	18%	20%	3%	3%	5%
Peer 4	$\mathbf{\times}$	×	×	3%	×	3%	×
Peer 5	3%	×	×	×	×	$\mathbf{\times}$	×
Peer 6	8%	×	3%	×	×	×	\mathbf{X}
Peer 7	$\mathbf{\times}$	3%	3%	×	3%	3%	×
Peer 8	\bigotimes	\mathbf{x}	\mathbf{x}	\bigotimes	5%	\bigotimes	\bigotimes

Source: NMG survey; \bigotimes = no citations

Percentages represent the total number of 'Best in Class' nominations for each reinsurer divided by the total number of respondents who answered this question.

Main motivation: improvement of capital efficiency Structured financial solution usage, US only 2015

All respondents




Source: NMG survey

Only factors cited by more than one key decision maker are shown

Capital funding has varying costs

Asset subordination view




Capital funding requirements

Maslow's hierarchy of needs

Business opportunities in a dynamic global environment

Our clients benefit from our deep knowledge of local markets and regulations



Hannover Re entities with special financial solutions expertise and offerings (Bermuda, Germany, Ireland, USA)

AG: Actuarial Guideline

C-ROSS: China Risk Oriented Solvency System PBR: Principle-Based Res LAGIC: Life & General Insurance Capital Standards RBC: Risk-Based Capital


LICAT: The Life Insurance Capital Adequacy Test SAM: Solveno PBR: Principle-Based Reserving

SAM: Solvency Assessment and Management

We are confident about the further development

Biggest "threats":

- Financial markets become predictable and stable
- Shareholders are happy with lower RoEs
- Competition decreases (FinTechs never take off)
- Regulators relax their requirements significantly
 - → Not the most likely scenario



A success story with a promising future

Disclaimer

This presentation does not address the investment objectives or financial situation of any particular person or legal entity. Investors should seek independent professional advice and perform their own analysis regarding the appropriateness of investing in any of our securities.

While Hannover Re has endeavoured to include in this presentation information it believes to be reliable, complete and up-to-date, the company does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such information.

Some of the statements in this presentation may be forward-looking statements or statements of future expectations based on currently available information. Such statements naturally are subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements.

This presentation serves information purposes only and does not constitute or form part of an offer or solicitation to acquire, subscribe to or dispose of, any of the securities of Hannover Re.

© Hannover Rück SE. All rights reserved. Hannover Re is the registered service mark of Hannover Rück SE.